NasdaqCM:CORTPharmaceuticals
Did FDA’s Relacorilant Setback and Probe Just Shift Corcept Therapeutics' (CORT) Investment Narrative?
In early February 2026, Kaplan Fox & Kilsheimer LLP began investigating potential securities violations at Corcept Therapeutics after the FDA issued a Complete Response Letter concluding it could not reach a favorable benefit‑risk assessment for relacorilant without more evidence of effectiveness.
This setback for a key pipeline candidate raises fresh questions about Corcept’s efforts to reduce dependence on its existing product base and diversify future revenue streams.
Next, we’ll examine...